Olink Proteomics. (3/12/19). "Press Release: Summa Equity Acquires Olink Proteomics".

	Organisation	Olink Bioscience AB (Olink Proteomics)
	Product	proteomics
	Product 2	private equity
	Person	Heimer, Jon (Olink 201510 CEO)

Summa Equity acquires Olink Proteomics, a Swedish life science company that has developed a unique technology for humanbiomarker discovery, targeting the global biopharma and academic research and discovery markets. Olink’s purpose is toenable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide. Summa Equity isexcited to support this development, and to continue building its base of investments within life science.

Summa Equity focuses on investments in companies that help solve global challenges. Olink Proteomics is providing a unique technologyto vastly improve our understanding of proteins within the human body. Proteomics, i.e. the large scale study of proteins, is one of the mostimportant areas for gaining insights in human biology and disease, as protein expression profiles are critical in reflecting states of health.The acquisition of Olink Proteomics is aligned with Summa Equity’s Changing Demographics theme and it supports the UN SustainableDevelopment Goal Target #3: “Ensure healthy lives and promote well-being for all at all ages”, by enabling improved treatment and patientoutcomes across a large number of disease areas.

Olink Proteomics was founded in 2004, based on pioneering research at Uppsala University, under the oversight of Prof. Ulf Landegrenand his team of researchers. The company has a unique technology for protein analysis, which provides substantial benefits over otherexisting technologies in the market by enabling a more efficient and precise analysis of much larger numbers of proteins. This technologyimproves understanding of the interaction of proteins and human disease, which is required to enable improved treatments within manyclinical areas.

The company has grown very rapidly over the past years, quickly expanding its scope of activities across the global market for life science,with a growing footprint across North America, Europe and Asia. Olink Proteomics is headquartered in Uppsala, Sweden, but also hasfacilities in the US. Olink Proteomics has approximately 110 employees across its current locations.

“The scientific and business opportunities for Olink Proteomics are enormous, as its technology is radically transforming the market forproteomics, thus enabling improved patient treatment. We look forward to supporting the company in its ambition to continue investing inimproved customer solutions, and its effort to roll out its technology on a world-wide basis,” said Tommi Unkuri, Partner at Summa Equity.

“We are very happy to have Summa Equity as our new owner. They have shown a deep understanding of our technology and the marketswe are addressing. They will be able to support us in scaling up our operations across markets, and drive benefit for customers, patientsand the research community,” said Jon Heimer, CEO of Olink Proteomics.

Summa Equity will be the majority shareholder in Olink Proteomics, whilst the management team and Ulf Landegren will remain asshareholders in the company. Summa Equity has been supported by a global team of advisors, including Moelis & Company LLC asfinancial advisor, White & Case as legal advisor, LEK Consulting as commercial advisor and KPMG as accounting advisor. J.P. MorganSecurities LLC served as Olink Proteomics’ financial advisor and Wiggin and Dana LLP and Lindahl served as its legal advisors.

For additional information, please contact:

Tommi Unkuri, Partner at Summa Equity, tommi.unkuri@summaequity.com
Jon Heimer, CEO of Olink Proteomics, jon.heimer@olink.com

About Summa Equity

Summa Equity is a lower mid-market Private Equity firm in the Nordics. It is a megatrend driven, thematic investment company focusing onResource Efficiency, Changing Demographics and Tech-enabled Businesses. Summa Equity is amongst the first Private Equity firms to committo the UN Sustainable Development Goals and its investments are aligned with these. Summa Equity was founded in 2016.

www.summaequity.com

About Olink Proteomics

Swedish company Olink Proteomics is a global leader for analysis of protein biomarkers in the field of precision medicine. Future health will besignificantly improved using biomarkers for disease prediction, monitoring and, diagnosis of patients with a higher degree of precision, allowingpatient to get the right treatment at the right point in time. Olink’s proprietary Proximity Extension Assay (PEA) technology enables researchersto look at unparalleled numbers of proteins in one simple experiment allowing all medical fields to get new insights driving this important fieldforward. The team at Olink Proteomics is dedicated to supporting the research community with a rapidly growing high-quality, validated proteintarget library which in the next couple of years will cover the essential part of the blood proteome. With over half a million samples analyzedand a team of specialist data scientists, Olink also has the expertise to maximize the success of protein biomarker studies. Olink Proteomics isheadquartered in Uppsala, Sweden, with a regional office and service laboratory for the U.S. organization in Watertown, MA.

www.olink.com

Record changed: 2023-06-05

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com